Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 75/100

Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

Key Takeaway: Ceribell, Inc. will present at the William Blair 45th Annual Growth Stock Conference on June 3, 2025. CEO Jane Chao will discuss the company's innovative EEG platform designed for acute care settings. The event highlights Ceribell's commitment to improving diagnosis and management of serious neurological conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is participating in a prominent investor conference.
  • The presentation will showcase innovative technology for neurological conditions.
  • Ceribell's system is FDA-cleared, indicating regulatory approval and safety.

Full Press Release Details

SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45thAnnual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.

Event: William Blair 45thAnnual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m. CST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website athttps://investors.ceribell.com/.
About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visitwww.ceribell.comor follow the company onLinkedIn.

Investor ContactBrian Johnston or Laine MorganGilmartin GroupInvestors@ceribell.com

Media ContactCorrie RosePress@ceribell.com

Frequently Asked Questions

When will Ceribell present at the conference?

Ceribell will present on June 3, 2025, at 7:20 a.m. PST.

Who is presenting for Ceribell?

Jane Chao, Ph.D., CEO and Co-founder, will present at the conference.

What is the focus of Ceribell's technology?

Ceribell focuses on transforming the diagnosis and management of neurological conditions.

Is Ceribell's EEG platform FDA-cleared?

Yes, the Ceribell System is FDA-cleared for detecting suspected seizure activity.

Last updated: May 20, 2025